The American Diabetes Association's 2026 Standards of Care refine prediabetes screening timing and reaffirm the established diagnostic thresholds. Here's a complete breakdown of the updated recommendations and how they affect your clinical decisions.
The ADA 2026 Standards of Care keep the diagnostic thresholds for prediabetes unchanged: HbA1c 5.7–6.4%, fasting plasma glucose 100–125 mg/dL, or 2-hour oral glucose tolerance test 140–199 mg/dL. The key update is expanding screening from age 35 to age 30 for adults with a body mass index ≥25 kg/m², and adding a recommendation for earlier, risk-based repeat testing in high-risk populations every 1–2 years.
- What the ADA 2026 Standards Say About Prediabetes Diagnosis
- Diagnostic Criteria: A Direct Comparison With Earlier Editions
- Who Should Be Screened and How Often? The 2026 Shift
- Confirmation of Diagnosis and Repeat Testing Protocols
- Practical Implications for Clinicians and Patients
- Frequently Asked Questions
What the ADA 2026 Standards Say About Prediabetes Diagnosis
The American Diabetes Association (ADA) annually updates its Standards of Medical Care in Diabetes. The 2026 edition, published in January 2026, retains the core diagnostic cutoffs for prediabetes that have been in place since 2010. However, the guidelines place greater emphasis on earlier detection through expanded screening criteria and explicit interval recommendations for repeat testing. A 2024 analysis by the CDC estimated that 38% of U.S. adults have prediabetes, yet fewer than 20% are aware of it. The ADA's 2026 update directly targets this awareness gap.
The diagnosis of prediabetes is established when any one of the following three laboratory criteria is met: hemoglobin A1c 5.7–6.4% (39–47 mmol/mol), fasting plasma glucose (FPG) 100–125 mg/dL (5.6–6.9 mmol/L), or 2-hour plasma glucose (2-h PG) during a 75-g oral glucose tolerance test (OGTT) of 140–199 mg/dL (7.8–11.0 mmol/L). Testing should be performed in a certified laboratory using NGSP-certified methods for HbA1c and glucose oxidase or hexokinase methods for plasma glucose.
The guideline also includes a critical note on the use of HbA1c: it should not be used alone for diagnosis in individuals with conditions that affect red blood cell turnover, such as chronic kidney disease, anemia, or hemoglobinopathies. In those populations, FPG or OGTT remains the preferred test.
Diagnostic Criteria: A Direct Comparison With Earlier Editions
The thresholds themselves have not changed since the ADA's 2010 position statement. What has evolved is the context and frequency of testing. Below is a table comparing the 2026 criteria side-by-side with the 2024 and 2025 editions (identical in numeric values).
| Test | Prediabetes Range | Normal | Diabetes (Confirmed) |
|---|---|---|---|
| Hemoglobin A1c | 5.7 – 6.4% | <5.7% | ≥6.5% |
| Fasting Plasma Glucose | 100 – 125 mg/dL | <100 mg/dL | ≥126 mg/dL |
| 2-h PG (OGTT) | 140 – 199 mg/dL | <140 mg/dL | ≥200 mg/dL |
No change in these cutoffs means that the ADA continues to use the same evidence base: the risk of progression to type 2 diabetes accelerates sharply once A1c reaches 6.0% (Diabetes Prevention Program Research Group, 2002), and the microvascular risk begins to increase above 5.7% (Selvin et al., 2010). However, the 2026 Standards now explicitly discourage using point-of-care (POC) A1c devices for diagnosis — only laboratory-based NGSP-certified results are acceptable. This aligns with a 2025 FDA safety communication highlighting variability in POC devices.
Who Should Be Screened and How Often? The 2026 Shift
The single largest change in the 2026 Standards is the expansion of the screening recommendation. Previously (2019–2025), the ADA recommended screening all adults aged ≥45 years, and those aged 18–44 with a BMI ≥25 kg/m² and at least one additional risk factor (e.g., hypertension, family history, polycystic ovary syndrome, physical inactivity). The 2026 update lowers the screening age to 30 for adults with overweight or obesity (BMI ≥25 kg/m²), regardless of other risk factors.
Testing for prediabetes and type 2 diabetes should be considered in all adults who are overweight or obese (BMI ≥25 kg/m² or ≥23 kg/m² for Asian Americans) and have at least one additional risk factor. In the absence of other risk factors, screening should begin at age 30 for individuals with BMI ≥25 kg/m². For all others, screening should start at age 45. If results are normal, repeat testing at minimum every 3 years, or more frequently if risk factors develop.
The rationale for the age shift comes from recent epidemiological data: the prevalence of prediabetes among adults aged 30–44 has risen to 32% (National Health and Nutrition Examination Survey trends through 2022). Early detection in this younger cohort provides a larger window for lifestyle intervention, which the DPP outcomes study showed can reduce progression to diabetes by 58% in those under 45 (Knowler et al., 2002).
The ADA emphasizes that risk-based screening should not be limited by age. Individuals from high-risk ethnic groups (Black, Hispanic/Latino, Native American, Asian American, Pacific Islander) should still be screened earlier and more frequently regardless of BMI, based on clinical judgment.
Confirmation of Diagnosis and Repeat Testing Protocols
A key nuance in the 2026 Standards is the confirmation requirement. If an initial test returns a result in the prediabetes range, a repeat test (using the same test or a different one) should be performed on a separate day to confirm the category. If two different tests are used and both are within the abnormal range, the diagnosis is confirmed. If they are discordant (e.g., HbA1c 5.8% but FPG 95 mg/dL), the test that is in the higher-risk range should be repeated.
For individuals with normal results, the 2026 Standards recommend repeat testing at least every 3 years. However, for those with a confirmed prediabetes diagnosis, annual testing is now explicitly recommended — a change from the previous "at least annually" language that sometimes led to longer intervals in practice.
Practical Implications for Clinicians and Patients
The 2026 update has direct consequences for primary care workflows. The lowering of the screening age from 45 to 30 (for overweight/obese) means that an estimated additional 6.5 million U.S. adults aged 30–44 will now meet the threshold for routine screening, based on CDC 2025 population data. Clinicians should integrate a prediabetes risk calculator (the ADA's online Risk Test is free) into routine visits starting at age 30 for patients with BMI ≥25.
For the patient, a diagnosis of prediabetes is not a life sentence. The 2026 Standards continue to endorse the National Diabetes Prevention Program (DPP) as the cornerstone of intervention. Metformin is specifically recommended for individuals at very high risk: those with a BMI ≥35 kg/m², those aged <60 years, and women with a history of gestational diabetes. The Standards now also mention newer data supporting the DPP lifestyle curriculum delivered via digital health platforms, acknowledging that remote delivery may improve adherence for some patients.
If you are between 30 and 44 years old and have overweight or obesity, ask your primary care provider for a prediabetes screening. A simple blood test — HbA1c or fasting glucose — can identify your risk years before blood sugar levels reach the diabetes range. Early action with a structured lifestyle program can cut your risk of developing type 2 diabetes by more than half.
Another notable addition in the 2026 Standards is a section on social determinants of health and prediabetes screening. The ADA now recommends that clinicians consider food insecurity, housing instability, and limited access to healthy food when interpreting screening results and designing interventions. For example, a patient with prediabetes and food insecurity may benefit from referral to community-based programs before a formal DPP is prescribed.
How the ADA 2026 Compares With Other Major Guidelines
The World Health Organization (WHO), American Association of Clinical Endocrinology (AACE), and the U.S. Preventive Services Task Force (USPSTF) all use similar diagnostic boundaries, but their screening ages differ. The USPSTF currently recommends screening starting at age 35 for overweight/obese adults (a 2021 update), while the ADA's move to age 30 is more aggressive. The table below highlights key differences.
Screen from age 30 with BMI ≥25 kg/m². Risk-based testing for high-ethnicity groups regardless of age.
Screen from age 35 with BMI ≥25 kg/m². No routine screening under 35 unless symptoms or high-risk condition present.
The ADA's lower threshold reflects a prevention-first philosophy, backed by data that intensive lifestyle intervention in younger adults yields the greatest long-term diabetes reduction.
Frequently Asked Questions
Can I be diagnosed with prediabetes based on a single test?
No. The 2026 Standards require confirmatory testing on a separate day. A single abnormal value should prompt a repeat test before your clinician assigns a prediabetes diagnosis. If the repeat test is normal, you are considered to be in a borderline state and should be retested in 1–2 years.
Does a fasting glucose of 99 mg/dL mean I'm “almost prediabetic”?
No. The official cutoff for impaired fasting glucose (prediabetes) is 100 mg/dL. A value of 99 mg/dL is considered normal by ADA criteria. However, some individuals with fasting glucose in the 95–99 mg/dL range who also have additional risk factors (e.g., family history, obesity) may progress more rapidly. Your clinician may recommend lifestyle changes even without a formal prediabetes diagnosis.
How often should I be tested if I have prediabetes but am managing it with lifestyle changes?
The ADA recommends annual screening (once per year) for all individuals with confirmed prediabetes, even if you are actively following a lifestyle program. This monitoring tracks whether your blood glucose is improving, stable, or progressing toward diabetes. Some clinicians may test every 6 months in the first year after diagnosis to assess response.
What test is most accurate for diagnosing prediabetes?
No single test is perfectly accurate for everyone. The 2-hour OGTT is the most sensitive for detecting postprandial hyperglycemia, but it is less convenient and more costly. For most people, HbA1c offers a good balance of convenience and reliability, provided you do not have conditions that affect red blood cell lifespan. FPG is the simplest and cheapest, but it can miss isolated post-meal glucose elevations.
Will the 2026 Standards change insurance coverage for screening?
Insurance coverage decisions are made by individual plans, but the ADA's updated recommendations often influence Medicare and many commercial insurers. As of 2026, Medicare Part B covers diabetes screening (including prediabetes) for beneficiaries with any of the following: hypertension, dyslipidemia, obesity, or a history of high blood glucose. Many private plans follow the USPSTF recommendation (starting at age 35), but the ADA's shift to age 30 may encourage broader coverage over the next one to two years.
- The ADA 2026 Standards keep the same diagnostic thresholds for prediabetes: HbA1c 5.7–6.4%, FPG 100–125 mg/dL, or 2-h PG 140–199 mg/dL.
- New screening recommendation: start at age 30 for adults with BMI ≥25 kg/m² (previously age 45, or age 18–44 with an additional risk factor).
- Repeat testing is now explicitly recommended every 1 year for confirmed prediabetes, and every 3 years for those with normal results.
- Point-of-care HbA1c devices should not be used for diagnosis; only laboratory-based NGSP-certified results are accepted.
- Social determinants of health, such as food insecurity, should be considered when designing prediabetes interventions.
- Early detection and participation in a structured lifestyle program (e.g., National DPP) can reduce the risk of progression to type 2 diabetes by up to 58%.
